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Introduction 24
The innovation of treatments for diseases remains a challenging task [1] [2] [3] [4] [5] [6] . The efficiency of pharmaceutical 25 research and development (R&D), quantified by the number of new drugs per billion US dollars spent, 26 dramatically declined from 1950 to 2010 [2] . A large group of drug candidates fail in clinical trials because 27 they are not effective or safe in humans [2, 5, [7] [8] [9] . A major reason is that the systematic effects of drug 28
candidates are not well studied or modelled in the drug discovery process, and a better understanding of 29 their mechanisms of action (MoA) can help improve the efficiency of drug R&D [2, [10] [11] [12] . 30
Two types of computational approaches have been reported to study MoAs of drugs by modeling high-31
throughput biological data: comparative analysis and network-based algorithms [13, 14] . Comparative 32 analysis approaches, such as the Connectivity Map [15] , have been used to predict molecular targets of 33 drugs and assist in drug repurposing [15] [16] [17] [18] [19] [20] . They utilize expression profiles as drug signatures and 34 compare with drugs having known targets, assuming that drugs with high similarities share the same targets. 35
These approaches much rely on prior knowledge of drugs, thus have limitations in predicting de novo 36 targets. 37
Network-based algorithms predict drug or disease targets by combining network information and 38 transcriptomic data [14, [21] [22] [23] [24] [25] [26] [27] . Two recent representatives, DeMAND [22] and ProTINA [14] , model the 39 systemic dysregulation of regulatory network caused by a drug treatment, connecting molecular interactions 40 with differential expression (DE) . The regulatory network is generated by using protein-protein interactions 41 (PPIs) and protein-gene interactions (PGIs) obtained from self-curated or public databases, such as 42 STRING [28] and CellNet [29] . Similar to what has been reported by Noh et al [14] , our preliminary 43 research showed that ProTINA outperforms DeMAND when tested by the same gene expression and 44 network datasets ( Figure S1 ). Therefore, in this work, we focused on studying ProTINA's performance. 45
For ProTINA, a regulatory network, directing from proteins or transcriptional factors (TFs) to regulated 46 genes, is generated from input PPIs and PGIs based on certain rules (Figure 1 ) [14] . The assumption is that 47 the log fold change (LFC) of a gene is the linear combination of the LFCs of all proteins and TFs that 48 regulate it. The weights are computed by linear regression methods and then integrated into a score for each 49 regulator, a protein or a TF. Different from DeMAND, ProTINA may result in negative or positive scores, 50
representing attenuation or enhancement, respectively. Regulators of larger magnitudes are more likely to 51 be targets (red nodes in Figure 1 ). Showing promising results in predicting in vitro datasets, DeMAND and 52
ProTINA have provided a new direction in identifying drug targets and toxicity [14, 22] . 53 54 Figure 1 . An overview of ProTINA algorithm. Each node refers to a transcription factor (TF), a non-TF 55 protein (P) or a gene (G). Arrows present the directions of interactions or edges. The significance of an 56 edge or protein (including TFs) is color coded, where red refers to high significance while blue refers to 57 low significance. 58 59 However, as target inference algorithms become more complicated, it is unclear what roles gene expression 60 and network data play. A recent study has shown that an accurate description of network topology is able 61
to cover 65% of the perturbation patterns predicted by a full biochemical model with kinetic parameters 62 [30] . Several studies have shown that proteins associated with disease and proteins that are drug targets 63
have significantly different positions within biological networks [31] [32] [33] [34] . For target inference algorithms, 64
it remains an open question as to which kind of biological data most affects the accuracy. Furthermore, 65
algorithms can infer drug targets in a cell/tissue type-specific manner [14, 22, 27] , and it is unknown how 66 efficient or meaningful cell/tissue type-specific network data is for target inference. Answering these 67
questions can provide us with insights into future algorithm improvement. 68
In this work, we evaluated the impact of gene expression and network data, using the human B cell 69 microarray data from the DREAM challenge (referred to as DP14) as our benchmark dataset [35] , and 70
introduced a new algorithm to predict drug targets. Firstly, we found that ProTINA's scores are mostly 71 determined by network data through permutation tests on gene expression. Secondly, we tested how the 72 selection of networks affects prediction accuracy. Surprisingly, the effects of size or cell type are negligible. 73
Next, our analysis suggested that network betweenness values can accurately predict drug targets. The 74
performance is comparable with ProTINA and is consistent regardless of the network size. Lastly, we 75
proposed TREAP to combine betweenness values and adjusted p-values from DE for target inference, 76
which has outperformed ProTINA in accuracy. Moreover, the simplicity of the algorithm makes it more 77 tractable to users who are not experts in systems and network biology. Our future work will focus on better 78
balancing both types of data and trying other methods, such as machine learning, to improve prediction 79 accuracy. 80
Materials and Methods 81

Gene expression data used in the analysis 82
The microarray data of human Diffuse Large B-Cell Lymphoma (DLBCL) OCI-LY3 cell line treated with 83 14 different drugs under diverse doses at 3 time points, 6, 12 and 24 hours post treatment were obtained 84 from the NCI-DREAM challenge drug synergy dataset, DP14 (GEO accession: GSE51068) [35] . Three 85 samples treated with 'Aclacinomycin A' under a lower dose were dropped due to less significance. The 86 microarray data of human liver cell line HepG2 treated with 62 genotoxic or non-genotoxic chemicals at 87 12, 24 and 48 hours post treatment were obtained from literature, referred to as HepG2 in this work (GEO 88 accession: GSE28878) [36] . The microarray data of mouse pancreatic cells treated with 29 chromatin-89 targeting compounds were also obtained from GEO database, referred to as MP (GEO accession: 90 GSE36379) [37] . For all three datasets, raw data were normalized using the RMA function from the "affy" 91 R package [38] . The log2 fold change (LFC) values and Benjamini-Hochberg adjusted p-values (adjusted 92 p-values) were calculated by the "limma" R package [39] . Probes were mapped to gene symbols by using 93 the "hgu219.db" R package for human microarray data and "moe430a.db" for mouse data. Those with the 94 lowest average BH-adjusted p-value across all samples were chosen when multiple probes were mapped to 95 the same gene. 96
Networks used in the analysis and calculation of topological features 97
Human or mouse PPIs and their associated confidence scores were obtained from the STRING database 98
[28]. Interactions with experimental proof or from curated databases (the channels of 'experiments' and 99 'databases') were extracted. Interactions transferred from other species or duplicated entries were excluded. 100
Subnetworks were obtained by applying thresholds ranging from 0.4 to 0.9 to the PPI network, referred to 101 as PPI04, PPI05, PPI06, PPI07, PPI08 and PPI09, respectively in this paper. 102
Human PGIs and their confidence scores were obtained from the Regulatory Circuits, a database of 103 predicted, cell/tissue type-specific PGIs [40] . PGI networks of 8 different cell/tissue types were studied in 104 this analysis: 'lymphocytes of B lineage', 'lymphocytes', 'lymphoma', 'myeloid leukocytes', 'lung', 'heart', 105
'epithelial cells' and 'hepatocellular carcinoma cell line'. The network of 'lymphocytes of B lineage' were 106 predicted by samples including those from DLBCL, the same cell line with DP14 [40], thus was chosen as 107 a reference for analysis of DP14. PGI subnetworks for each cell/tissue type, namely PGI05, PGI10, PGI15 108 and PGI20, were obtained by thresholds ranging from 0.05 to 0.20, respectively. Mouse PGIs were 109 compiled from two manually curated databases of transcriptional regulatory networks: TRRUST (version 110
2) [41] and RegNetwork [42] . These interactions are not cell/tissue type-specific, and no threshold was 111 applied to them prior to analysis of MP. 112
Degree or betweenness values were calculated by the "igraph" R package [43] . PPIs or the combination of 113
PPIs and PGIs (PPI+PGI) were treated as undirected graphs, while PGIs were treated as directed graphs. 114
Reference drug targets 115
The reference targets of each chemical were extracted from STITCH database (version 5.0) [44, 45] for 116 analyses of DP14, HepG2 and MP. Only targets with experimental proof or from curated databases were 117 collected as shown in Table S1 . 118
Prediction of drug targets by ProTINA 119
LFC values, PPI and PGI subnetworks were analyzed by "protina" R package [14] . Slope matrices of each 120 time point were calculated following the user manual. For samples with only two timepoints, control 121 samples served as 0hr post treatment to calculate associated slope matrices. Samples from different doses 122
for the same drug were treated as separate groups. 123
Prediction of drug targets by TREAP 124
For target prediction by TREAP, the assumption is that genes with high betweenness values or low adjusted 125
p-values are more likely to be drug targets. Adjusted p-values and PPI+PGI betweenness values were 126 calculated as explained in the former sections. Ranks of genes were obtained by sorting betweenness values 127 and adjusted p-values, respectively, and genes with the same betweenness or adjusted p-value shared the 128 same rank. Final scores were calculated by summing up the ranks from both metrics for each gene. In this 129
work, all analyses on TREAP used 0.9 as the threshold for human or mouse PPIs and 0.20 for human PGIs.
130
No threshold was applied to mouse PGIs. 131
Calculation and comparison of AUROC values 132
Area under the receiving operator characteristics (AUROC) values in this paper were calculated by 133
comparing scored proteins with reference drug targets through the "pROC" R package [46] . As ProTINA 134 scores can be positive or negative, the absolute scores were used to calculate AUROC. The median AUROC 135 across all drugs in each dataset was calculated to represent accuracy of a whole test. For drugs having more 136 than one doses, the AUROC values of low doses were excluded. In terms of topological features, degree or 137 betweenness values were directly used to calculate AUROC values without pre-processing. TREAP scores 138
were directly used for calculation of AUROC without preprocessing. Difference in any pair of chosen tests 139
were computed by performing pairwise t-test between their AUROC values. A p-value less than 0.05 were 140
regarded as significantly different. 141
Permutation tests on gene expression 142
The null hypothesis for permutation tests in this work is that the median AUROCs of randomized gene 143 expression are smaller than that of nonrandomized gene expression, and the p-values were calculated 144 accordingly. For ProTINA, gene labels for DP14 that refer to the rows of LFC and associated slope matrices 145
were randomly shuffled for 1000 times. Randomized data were applied to ProTINA under the same network 146 setup, PPI09 and PGI20. For TREAP, gene labels of adjusted p-values for each dataset, namely DP14, 147
HepG2 and MP were randomly shuffled for 1000 times, respectively, and drug targets were predicted using 148 PPI09 and PGI20 (for MP no threshold was applied). AUROC and median values were calculated as 149 explained in the former section. 150
Results 151
Permutation tests show that ProTINA is predominantly determined by network data 152
To understand how much network or gene expression data contribute to ProTINA's accuracy, we performed 153 1000 permutation tests by randomizing the LFC gene expression values (Materials and Methods). To 154 shorten the computation time on ProTINA, the smallest PPI and PGI subnetworks (PPI09 and PGI20) were 155 chosen for this analysis (discussed more in the following section). For prediction scores obtained from 156
ProTINA, the area under the receiver operating characteristics (AUROC) values were calculated per drug, 157 and the median AUROC across all drugs is used as a metric for each test. 158
The median AUROC obtained by nonrandomized LFCs is 0.799. As shown in Fig. 2 
Selection of networks has limited effects in the prediction accuracy of ProTINA 167
Next, we studied how the selection of PPIs and PGIs affects target inference accuracy. PPI and PGI 168 subnetworks of different sizes or cell/tissue types were tested using the same gene expression data from 169 DP14 (Materials and Methods). Similar to permutation tests, the median AUROC represents the accuracy 170
for each PPI-PGI combination. 171
In total, 24 PPI-PGI combinations of different sizes were tested on ProTINA. As shown in Figure 3a , 172
ProTINA favors small PPI and large PGI subnetworks. The combination of PPI09 and PGI05 shows the 173 highest accuracy, and its median AUROC is 0.821. As the threshold increases from 0.4 to 0.9, the number 174 of interactions in PPI subnetwork ranges from 380375 to 281357 ( Figure S2 ), and the median AUROC 175
increases for most tests. For example, the median AUROC increases from 0.785 (PPI04) to 0.811 (PPI09) 176
for analyses under PGI10. But there are PPI subnetworks that do not follow this trend. Under PGI05, PPI05 177
shows lower median AUROC than PPI04 (0.784 and 0.796, respectively). For PGI subnetworks, as the 178 number of interactions range from 123394 to 5932 ( Figure S2 ), the median AUROC shows an opposite 179 trend to that of PPI subnetworks (Figure 3a ). An example is that the median AUROC decreases from 0.821 180 (PGI05) to 0.785 (PGI20) when using PPI09. Most tests show a consistent trend except for those using 181 PPI05. A possible reason is that new proteins and associated interactions are included in the network as the 182 threshold for PGIs changes from 0.05 to 0.10. So that the network topology is changed, and predictions 183
from ProTINA are affected accordingly. 184
However, median AUROC values vary in a small range while the size of PPI or PGI subnetworks changes 185 significantly (Figure 3a, 3b and Figure S3 ). The highest and lowest median AUROC values for ProTINA 186 are 0.821 and 0.753, with a difference less than 0.1 (Figure 3b ). In addition, most of these differences are 187 insignificant. When comparing with the test using PPI09 and PGI20, none of the 24 tests are significant in 188 AUROC values (p-value > 0.05 for all tests), although the combination of PPI04 and PGI15 has resulted in 189 a pairwise p-value of 0.057. Furthermore, we studied the effects on standard deviations (SDs) of AUROC 190 values across 12 drugs for each test. All of them maintain at a low level below 0.13. In summary, we 191
conclude that the size of networks has limited effects on the prediction accuracy of ProTINA, while small 192 PPI and large PGI networks tend to improve the accuracy. To analyze the performance of cell/tissue type-specific networks, 28 tests using PGIs from 7 cell/tissue 203 types were performed on ProTINA using the same PPI subnetwork, PPI09. Most tests counterintuitively 204
show similar median AUROC values regardless of cell/tissue types (Figure 3c, Figure S4 ). In theory, the 205 PGI subnetworks for immune cells should have higher accuracy than non-immune cell types, and those for 206
'lymphocytes of B cell lineage' should outperform other immune cells. This is because that samples from 207 DLBCL, the same cell line with DP14, were used to predict the interactions for 'lymphocytes of B lineage' 208
[40] (Materials and Methods). However, using the AUROC values from PGI20 for 'lymphocytes of B cell 209 lineage' as a reference, no other cell/tissue types are significantly different (pairwise p-values > 0.05 for 210
all) under the same network setup. In conclusion, we have shown that the selection of PPIs or PGIs in terms 211 of either the size or cell/tissue type is not the key factor to prediction accuracy of ProTINA. 212
Topological features have similar prediction accuracy to ProTINA, and protein betweenness 213 outperforms degree 214
Our findings have shown that ProTINA depends on network topology more than gene expression, and that 215 it has consistent performance regardless of the network size or the cell/tissue type the network represents. 216
These suggest that ProTINA is probably determined by some network topological feature that remains 217
relatively stable across different PPI or PGI subnetworks, such as protein degree or betweenness. The 218 degree of a protein is the number of proteins/genes with which it interacts, while the betweenness is a 219 measure of bottleneckedness, e.g. the amount of information flowing through the proteins that connect the 220 rest of the network. Analyses of these features and their effects on drug target prediction may provide 221 meaningful insights on improving prediction accuracy. 222
To test our hypotheses, we studied degree and betweenness values for PPIs, PGIs and PPI-PGI 223
combinations (referred to as PPI+PGI in the following text). Firstly, for PPIs, we compared scores obtained 224
from ProTINA (using PPI09 and PGI20) with their associated protein degrees or betweenness values in 225
PPI09 for each drug. The majority of the drugs show a weak but evident correlation between absolute 226
ProTINA scores and protein degrees, however, the correlation for betweenness is much lower (Table S2) .
227
For instance, the correlation coefficient is 0.211 for 'Rapamycin' (Figure 4a ), while the correlation of 228 betweenness values is smaller than that of degrees, which is 0.085 for the same drug (Figure 4b ). Notice 229 that a large portion of the top 100 proteins scored by ProTINA (red points in Figure 4a , b) lie in the group 230 of high degree or betweenness values. 231
We next tried to predict drug targets by using PPI degree or betweenness values without considering gene 232 expression or PGIs. The assumption is that proteins with higher degree or betweenness values are more 233 likely to be targets. As shown in Figure 4c , the median AUROC values for PPI degree or betweenness 234
values are close to those for ProTINA. What's more, betweenness values perform better than degrees. The 235
highest and lowest median AUROC values for degrees are 0.814 and 0.727 (Figure 4c ), and those for 236 betweenness values are 0.866 and 0.800, even higher than associated median AUROC values for ProTINA 237 under the same network setup. As the size of PPI subnetworks shrinks, the median AUROCs for degrees 238 decreases accordingly (Figure 4c) , with a correlation coefficient value of -0.950 between the medians and 239 thresholds. While the decrease of network size also diminishes the accuracy of betweenness, the median 240
AUROCs remain higher than those of degrees and decrease relatively slower. 241 degree and betweenness values were used to predict drug targets assuming higher scores are more likely to 246
be targets. Each point shows the median AUROC value and the number of proteins under a PPI threshold. 247
For reference, the grey dashed line refers to the highest median AUROC achieved by ProTINA, which was 248 obtained from using PPI09 and PGI05. 249 250 Secondly, the degree and betweenness values of PGI subnetworks were also compared with associated 251
ProTINA scores, however, there are no clear trends between them (Table S2 ). In addition, drug target 252 prediction based on PGI degree or betweenness values are not comparable with that by PPI topological 253 features ( Figure S5 ). This might be related to the limited amount of PGI interactions. 254
Lastly, we calculated topological features for PPI+PGI and compared them with ProTINA scores. As 255 expected, they show the same trend with PPIs (Table S2 ). The correlation coefficient between degrees and 256
ProTINA scores is 0.208 for 'Rapamycin', while that for betweenness values is 0.079 (Figure 5a, b) . 257
Predicting drug targets by PPI+PGI degree or betweenness values results in higher median AUROC values 258 than those for PPIs. In addition, for all thresholds of PPIs or PGIs applied to this analysis, betweenness 259
values outperform degrees. The accuracy for PPI+PGI degrees ranges from 0.833 to 0.733 in terms of 260
median AUROC values, and that for betweenness values ranges from 0.878 to 0.782 (Figure 5c ). As the 261 size of PPI or PGI subnetworks decreases, the median AUROC values for PPI+PGI degrees also decreases.
262
PPI+PGI betweenness values have the same behavior as the size of PPIs changes, while for PGIs the trend 263 is less evident. PGI10 has the best performance in parallel comparisons. In summary, betweenness values 264 well predict drug targets and show even higher accuracy than ProTINA. for 'Rapamycin'. The correlation coefficient for absolute ProTINA scores versus degrees and absolute 268
ProTINA scores versus betweenness values is 0.208 and 0.079, respectively. Red points refer to the top 100 269 proteins scored by ProTINA. (c) The degree and betweenness values were used as measures to predict drug 270 targets, and the median AUROC values were calculated for each prediction. The axes refer to the confidence 271 thresholds for PPI (x axis) and PGI (y axis) subnetworks. 272
Missing information in network topology can be covered by differential expression 273
Topological features, degree or betweenness values, have shown high prediction accuracy without taking 274 gene expression into account. Our permutation tests have also indicated that network data has more effects 275
in ProTINA's performance than gene expression data. What's more, ProTINA has much better performance 276 than differential expression (DE) analysis on drug target prediction according to prior research [14] . All of 277 the above has raised a question about whether gene expression data can help to predict drug targets. To 278 address this concern, we compared DE analysis (adjusted p-values, Materials and Methods) with two other 279 target prediction methods in terms of their performance on each drug: PPI+PGI betweenness and ProTINA. 280
We calculated AUROC values for all three methods using the same network setup, PPI09 and PGI20 281
( Figure 6 ). For most drugs, such as 'Mitomycin C' or 'Cycloheximide', PPI+PGI betweenness and 282
ProTINA have close AUROC values, and they outperform DE analysis. Consistent behaviors between 283
ProTINA and PPI+PGI further indicates the impact of network topology on ProTINA's accuracy. In 284 contrast to these drugs, DE has much higher prediction accuracy than PPI+PGI or ProTINA for 'Monastrol' 285 (the AUROCs are 0.998, 0.771 and 0.555, respectively). This means that DE analysis of gene expression 286
data can capture information missing in network topology, and that it is necessary to include gene 287 expression data for drug target inference and improvement of accuracy. 288 289 Figure 6 . AUROC values of each drug obtained from three different methods: differential expression (DE) 290
analysis by adjusted p-values, betweenness values from the combination of PPI09 and PGI20 (PPI+PGI) 291
and ProTINA analysis by PPI09 and PGI20. 292
A novel algorithm that combines network topology and DE analysis for target inference 293
To better combine network topology and DE analysis and improve inference accuracy, we suggest TREAP 294 (target inference by ranking betweenness values and adjusted p-values) to predict drug targets. There are 295 three steps for this algorithm. AUROCs > 0.800, Figure 7 ). While TREAP takes significantly less computation time than ProTINA, it has 310
higher median AUROCs when compared with ProTINA under the same dataset (Figure 7) . For DP14, the 311 median AUROC of TREAP is 0.850, higher than that of ProTINA, 0.799 (p-value = 0.11). Notice that it is 312 also higher than using PPI+PGI betweenness values alone, which is 0.798. TREAP significantly 313
outperforms ProTINA in HepG2. The median AUROC is significantly improved from 0.739 to 0.801, with 314 a p-value of 0.0002. For MP, TREAP and ProTINA have close median AUROCs as 0.806 and 0.799, 315 respectively (p-value = 0.39). By integrating betweenness values and adjusted p-values to represent both 316 network topology and DE analysis, TREAP is comparable with and sometimes better than ProTINA in 317 accuracy for all datasets analyzed in this work. In addition, we performed 1000 permutation tests on TREAP 318
by randomizing the adjusted p-values for each dataset. Different from ProTINA, TREAP is significant when 319 compared with permutation tests on the adjusted p-values from DP14, with the one-tailed p-value as 0.007 320 ( Figure S6 ). For HepG2, the one-tailed p-value is 0.058, while for MP, TREAP is less significant and shows 321 a one-tailed p-value as 0.314. Our analyses have shown that, even though ProTINA requires both gene expression and network data for 328 inputs, network data predominantly determines accuracy of drug target inference. What's more, the 329 cell/tissue type or size of a network has limited impact on ProTINA's accuracy, while topology, especially 330 the degree value, affects the performance of ProTINA more. 331
However, ProTINA has two limitations due to the reliance on network topology alone and the connection 332 with protein degrees. First, PPIs, a major part of network data, have a known bias toward protein abundance 333 [33, 47] . It has been reported that interactions obtained from high-throughput experiments have a 334 correlation between the protein degree and abundance. Second, we have shown that differential analysis of 335 gene expression data can uncover meaningful information missing in network topology. 336
To address these two limitations, we suggested a new algorithm, TREAP, which combines protein 337 betweenness values and adjusted p-values, representing information from both sources of network topology 338 and DE analysis, to predict drug targets. We chose betweenness values because they are less sensitive to 339 network sizes and more accurate than degrees in target prediction. TREAP shows more consistent 340
performance than ProTINA when tested by different gene expression profiles and maintains a median 341 AUROC above 0.800. In addition, TREAP takes significantly less computation time than ProTINA, and its 342 simplicity makes it more tractable to users who are not experts in systems and network biology. It is also 343 flexible in dealing with samples of limited or multiple timepoints as adjusted p-values can be calculated per 344 timepoint or across all timepoints based on user's needs. However, ProTINA needs at least two timepoints 345
to fully take advantage of the algorithm [14] . Currently, betweenness values and adjusted p-values are 346
weighted equally for TREAP. Future work should focus on better balancing both types of data and trying 347
other scoring methods to improve prediction accuracy. 348 TREAP is presented here as an alternative approach to ProTINA, but it is worth emphasizing advantages 349 specific to each algorithm. As stated above, TREAP is significantly faster, and the algorithm is not complex, 350
enabling users from several branches of research to access the tool and understand the findings. ProTINA, 351
however, is a mechanistically derived algorithm, which allows users with expertise in computational 352 biology to dive deeper into the possible mechanisms of a drug's activity. The accuracy of their predictions 353 is similar when measured using the AUROC, but the permutation tests presented here suggest that TREAP 354
is more likely to use drug-specific gene expression to make a more accurate prediction. 355 TREAP and its derivatives have potential in a variety of applications for drug innovation. First, it can assist 356
in selection of drug candidates and serve as a preliminary test of the efficacy or safety by connecting with 357 databases for functional annotations, e.g. Gene Ontology [48, 49] . Studying predicted targets can help 358 exclude poorly targeting drug candidates or those causing severe damage to biological systems. Second, 359
the algorithm can be applied to drug repurposing by exploring published datasets characterizing drug 360 treatments, assuming that a pair of drugs sharing the same group of predicted targets can be used to treat 361 the same disease. Last but not the least, the algorithm can help to discover disease mechanisms [14] . Similar 362 to drug treatments, diseases can also be treated as a type of perturbation to the biological system of interest. 363
Predicting disease targets may assist in identifying key components of disease mechanisms and pathology, 364
which is crucial for innovations in disease treatment [10] . Figure S1 : Comparing the accuracy of ProTINA and DeMAND; Figure S2 : 372
The number of interactions under different thresholds for PPIs and PGIs; Figure S3 : Performance of 373
ProTINA on DP14 using PPIs and PGIs of different sizes; Figure S4 : Performance of ProTINA on DP14 374
using PGIs from different cell/tissue types; Figure S5 : Predicting drug targets by degree or betweenness 375 values of PGIs; Figure S6 : Median AUROCs of permutation tests on TREAP. Table S1 : Reference drug 376 targets for each analysis; Table S2 : Correlation coefficients between degree or betweenness values and 377
ProTINA scores for each drug; Table S3 : AUROCs of each drug for ProTINA, topological features and 378 TREAP; Table S4 : Degree and betweenness values of proteins under different thresholds. 379
